X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/25/2869647/0/en/Apollomics-Announces-Approval-of-Vebreltinib-in-China-as-a-First-in-Class-Treatment-for-Gliomas-with-MET-Fusion-Gene.html
https://www.globenewswire.com/news-release/2024/04/10/2860624/0/en/Apollomics-Presents-Vebreltinib-Data-at-the-2024-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/04/05/2858738/0/en/Predicine-Announces-Collaboration-with-Apollomics-to-Develop-PredicineCARE-as-a-Companion-Diagnostic-Assay-in-Lung-Cancer.html
https://www.globenewswire.com//news-release/2024/01/19/2812510/0/en/Apollomics-Receives-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html
https://www.globenewswire.com//news-release/2024/01/17/2811146/0/en/Apollomics-to-Participate-in-a-Fireside-Chat-at-the-B-Riley-Securities-2024-Virtual-Oncology-Conference.html
https://www.globenewswire.com//news-release/2024/01/02/2802952/0/en/Apollomics-to-Present-at-the-2024-Biotech-Showcase.html
https://www.globenewswire.com//news-release/2023/10/26/2767559/0/en/Apollomics-Announces-Report-of-Activity-of-Vebreltinib-in-Glioblastoma-Multiforme-GBM-with-PTPRZ-MET-Fusion.html
https://www.globenewswire.com//news-release/2023/10/16/2761121/0/en/Apollomics-Announces-Presentations-of-Vebreltinib-Data-at-ESMO-2023.html
https://www.globenewswire.com//news-release/2023/09/28/2751645/0/en/Apollomics-Reports-First-Half-2023-Financial-Results-and-Provides-Corporate-Update.html
https://www.globenewswire.com/news-release/2023/03/30/2637587/0/en/Apollomics-a-Company-Developing-Novel-Oncology-Therapies-to-Address-Difficult-to-Treat-Cancers-Announces-Closing-of-Business-Combination-and-Listing-on-Nasdaq.html
Market Place
Share 
